International phase IV validation study of an EORTC quality of life questionnaire for testicular cancer patients: the EORTC QLQ-TC26

Table 5 QLQ-TC26 scores at the start of treatment, the end of treatment and post-treatment

	On-Treatment							Post-Treatment
	T1on N = 113		T2on N = 49			T1on vs T2on^a		T1post N = 200		T2on vs T1post^a
EORTC QLQ-TC26	Mean	SD	Mean	SD	Diff.	F-statistic	p-value	Mean	SD	t-statistic	p-value
Treatment Side Effects	12.3	15.1	17.1	15.2	4.8	10.841	0.002**	9.3	13.9	3.252	0.002**
Treatment Satisfaction	89.1	21.0	91.2	16.4	2.1	0.687	0.410	90.4	22.7	0.230	0.818
Future Perspective	61.9	27.4	65.3	23.0	3.4	0.339	0.563	66.9	26.9	−0.386	0.700
Family Problems	36.6	34.2	34.7	27.5	−1.9	0.481	0.491	22.8	29.7	2.537	0.012*
Infertility	36.6	37.3	27.9	31.4	−8.7	2.824	0.099	28.5	33.5	−0.115	0.908
Communication	81.7	26.1	83.7	23.9	2.0	1.022	0.316	82.3	24.1	0.350	0.727
Body Image Problems	13.6	23.8	23.6	33.7	10.0	6.124	0.016*	12.8	22.3	2.110	0.039*
Sexual Activity	54.9	29.0	40.5	31.4	−14.4	10.636	0.002**	63.7	27.2	−5.178	< 0.001**
Sexual Functioning	91.3	20.2	91.7	16.0	0.4	0.027	0.871	86.4	23.2	1.646	0.105
Job Education problems	32.4	35.8	16.3	24.6	−16.1	7.043	0.011*	12.5	26.6	0.915	0.361
Physical limitations	32.4	33.5	36.1	29.5	3.7	1.054	0.308	15.3	27.1	4.710	< 0.001**
Sexual Enjoyment	78.6	27.0	70.6	28.4	−8.0	5.410	0.025*	78.4	25.6	−1.613	0.108
Testicular Implant Satisfaction	45.8	40.4	56.9	42.1	11.1	0.391	0.541	66.7	34.3	−0.973	0.334

^aT1on - first assessment time point in the on-treatment group before treatment start; T2on - second assessment time point in the on-treatment group at the end of treatment; T1post - first assessment time point in post-treatment group;
*p< .05, **p< .01

ISSN: 1471-2407